NTI — Neurotech International Share Price
0.000.00%
Last trade - 00:00- AU$30.22m
- AU$24.26m
- AU$3.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.27 | ||
| Price to Tang. Book | 5.27 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.85 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -205.39% | ||
| Return on Equity | -223.8% | ||
| Operating Margin | -345.21% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.08 | 0.21 | 0.61 | 1.25 | 3.34 | n/a | n/a | 67.39% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.
Directors
- Brian Leedman NEC
- Peter Griffiths CEX
- Angelica Trigona CMO
- Emanuela Russo CSO
- Mario Raciti OTH
- Erlyn Dale SEC
- Krista Bates NED
- Allan Cripps NED
- Winton Willesee NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 15th, 2016
- Public Since
- November 4th, 2016
- No. of Shareholders
- 2,539
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 1,042,121,921
- Address
- Suite 5 CPC, 145 Stirling Highway, NEDLANDS, 6009
- Web
- https://neurotechinternational.com/
- Phone
- +61 893893130
- Auditors
- BDO Audit (WA) PTY LTD
Upcoming Events for NTI
Similar to NTI
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Neurotech International share price?
As of Today at 03:14 UTC, shares in Neurotech International are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the Neurotech International share price performed this year?
Shares in Neurotech International last closed at AU$0.03 and the price had moved by -70.41% over the past 365 days. In terms of relative price strength the Neurotech International share price has underperformed the ASX All Ordinaries Index by -70.55% over the past year.
What are the analyst and broker recommendations for Neurotech International?
There is no consensus recommendation for this security.
Find out moreWhat is the Neurotech International dividend yield?
Neurotech International does not currently pay a dividend.
Does Neurotech International pay a dividend?
Neurotech International does not currently pay a dividend.
When does Neurotech International next pay dividends?
Neurotech International does not currently pay a dividend.
How do I buy Neurotech International shares?
To buy shares in Neurotech International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neurotech International?
As of the previous close price of AU$0.03, shares in Neurotech International had a market capitalisation of AU$30.22m.
Where are Neurotech International shares listed?
Here are the trading details for Neurotech International:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NTI
What kind of share is Neurotech International?
Based on an overall assessment of its quality, value and momentum Neurotech International is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neurotech International share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Neurotech International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neurotech International. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -57.48%.
As of the last closing price of AU$0.03, shares in Neurotech International were trading -50.62% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neurotech International PE Ratio?
The Neurotech International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neurotech International?
Neurotech International's management team is headed by:
- Brian Leedman - NEC
- Peter Griffiths - CEX
- Angelica Trigona - CMO
- Emanuela Russo - CSO
- Mario Raciti - OTH
- Erlyn Dale - SEC
- Krista Bates - NED
- Allan Cripps - NED
- Winton Willesee - NED